Literature DB >> 18759344

Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6.

Christoph Globas1, Sophie Tezenas du Montcel, Laslo Baliko, Syliva Boesch, Chantal Depondt, Stefano DiDonato, Alexandra Durr, Alessandro Filla, Thomas Klockgether, Caterina Mariotti, Bela Melegh, Maryla Rakowicz, Pascale Ribai, Rafal Rola, Tanja Schmitz-Hubsch, Sandra Szymanski, Dagmar Timmann, Bart P Van de Warrenburg, Peter Bauer, Ludger Schols.   

Abstract

Onset of genetically determined neurodegenerative diseases is difficult to specify because of their insidious and slowly progressive nature. This is especially true for spinocerebellar ataxia (SCA) because of varying affection of many parts of the nervous system and huge variability of symptoms. We investigated early symptoms in 287 patients with SCA1, SCA2, SCA3, or SCA6 and calculated the influence of CAG repeat length on age of onset depending on (1) the definition of disease onset, (2) people defining onset, and (3) duration of symptoms. Gait difficulty was the initial symptom in two-thirds of patients. Double vision, dysarthria, impaired hand writing, and episodic vertigo preceded ataxia in 4% of patients, respectively. Frequency of other early symptoms did not differ from controls and was regarded unspecific. Data about disease onset varied between patients and relatives for 1 year or more in 44% of cases. Influence of repeat length on age of onset was maximum when onset was defined as beginning of permanent gait disturbance and cases with symptoms for more than 10 years were excluded. Under these conditions, CAG repeat length determined 64% of onset variability in SCA1, 67% in SCA2, 46% in SCA3, and 41% in SCA6 demonstrating substantial influence of nonrepeat factors on disease onset in all SCA subtypes. Identification of these factors is of interest as potential targets for disease modifying compounds. In this respect, recognition of early symptoms that develop before onset of ataxia is mandatory to determine the shift from presymptomatic to affected status in SCA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759344     DOI: 10.1002/mds.22288

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  43 in total

1.  Oculomotor deficits in spinocerebellar ataxia type 3: Potential biomarkers of preclinical detection and disease progression.

Authors:  Chao Wu; Ding-Bang Chen; Li Feng; Xiang-Xue Zhou; Ji-Wei Zhang; Hua-Jing You; Xiu-Ling Liang; Zhong Pei; Xun-Hua Li
Journal:  CNS Neurosci Ther       Date:  2017-02-13       Impact factor: 5.243

Review 2.  Consensus Paper: Neurophysiological Assessments of Ataxias in Daily Practice.

Authors:  W Ilg; M Branscheidt; A Butala; P Celnik; L de Paola; F B Horak; L Schöls; H A G Teive; A P Vogel; D S Zee; D Timmann
Journal:  Cerebellum       Date:  2018-10       Impact factor: 3.847

3.  Parametric fMRI of paced motor responses uncovers novel whole-brain imaging biomarkers in spinocerebellar ataxia type 3.

Authors:  João Valente Duarte; Ricardo Faustino; Mercês Lobo; Gil Cunha; César Nunes; Carlos Ferreira; Cristina Januário; Miguel Castelo-Branco
Journal:  Hum Brain Mapp       Date:  2016-06-07       Impact factor: 5.038

4.  Postural Instability in Prodromal Spinocerebellar Ataxia Type 2: Insights into Cerebellar Involvement Before Onset of Permanent Ataxia.

Authors:  Luis Velázquez-Pérez; Gilberto Sánchez-Cruz; Roberto Rodríguez-Labrada; Mercedes Velázquez-Manresa; Ricardo Hechavarría-Pupo; Luis E Almaguer-Mederos
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

5.  Retinal Nerve Fibre Layer and Macular Thinning in Spinocerebellar Ataxia and Cerebellar Multisystem Atrophy.

Authors:  John H Pula; Vernon L Towle; Victoria M Staszak; Dingcai Cao; Jacqueline T Bernard; Christopher M Gomez
Journal:  Neuroophthalmology       Date:  2011-06

Review 6.  The impact of histone post-translational modifications in neurodegenerative diseases.

Authors:  Samantha N Cobos; Seth A Bennett; Mariana P Torrente
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-10-20       Impact factor: 5.187

7.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

Review 9.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

10.  Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.

Authors:  Mercedes Prudencio; Hector Garcia-Moreno; Karen R Jansen-West; Rana Hanna Al-Shaikh; Tania F Gendron; Michael G Heckman; Matthew R Spiegel; Yari Carlomagno; Lillian M Daughrity; Yuping Song; Judith A Dunmore; Natalie Byron; Björn Oskarsson; Katharine A Nicholson; Nathan P Staff; Sorina Gorcenco; Andreas Puschmann; João Lemos; Cristina Januário; Mark S LeDoux; Joseph H Friedman; James Polke; Robin Labrum; Vikram Shakkottai; Hayley S McLoughlin; Henry L Paulson; Takuya Konno; Osamu Onodera; Takeshi Ikeuchi; Mari Tada; Akiyoshi Kakita; John D Fryer; Christin Karremo; Inês Gomes; John N Caviness; Mark R Pittelkow; Jan Aasly; Ronald F Pfeiffer; Venka Veerappan; Eric R Eggenberger; William D Freeman; Josephine F Huang; Ryan J Uitti; Klaas J Wierenga; Iris V Marin Collazo; Philip W Tipton; Jay A van Gerpen; Marka van Blitterswijk; Guojun Bu; Zbigniew K Wszolek; Paola Giunti; Leonard Petrucelli
Journal:  Sci Transl Med       Date:  2020-10-21       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.